Govt Bans Cough & Cold Medicine Combo for Children Under 4 Years
Source: ET Real Estate
Arth Insight · What this means for your wallet
- Medicines combining Chlorpheniramine Maleate and Phenylephrine Hydrochloride are now banned for children under four.
- Manufacturers must add clear warnings to packaging for these specific drug combinations.
- The decision follows recommendations from expert health committees.
Wealth-Impact Simulator
See how a change in interest rates hits your loan EMI.
Indicative estimate for education only — not investment advice.
Compare loan ratesThe Indian government has prohibited the use of fixed-dose combinations containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride for children below four years of age. Manufacturers are now mandated to display clear warnings on all product packaging.
- ▸Medicines combining Chlorpheniramine Maleate and Phenylephrine Hydrochloride are now banned for children under four.
- ▸Manufacturers must add clear warnings to packaging for these specific drug combinations.
- ▸The decision follows recommendations from expert health committees.
- ▸Parents should always check medicine labels and consult doctors for young children's health issues.
- ✓Medicines combining Chlorpheniramine Maleate and Phenylephrine Hydrochloride are now banned for children under four.
- ✓Manufacturers must add clear warnings to packaging for these specific drug combinations.
- ✓The decision follows recommendations from expert health committees.
- ✓Parents should always check medicine labels and consult doctors for young children's health issues.
The Indian government has implemented a significant restriction on certain fixed-dose combination (FDC) medicines commonly used for cough and cold symptoms. These FDCs, which contain Chlorpheniramine Maleate and Phenylephrine Hydrochloride, are now explicitly prohibited for use in children under the age of four years.
This regulatory change, effective immediately upon its publication in the official gazette, mandates that all manufacturers of these specific drug combinations must prominently display a warning on their product packaging. The warning will alert consumers that the medicine is not suitable for young children.
Why the Restriction?
The decision to tighten these regulations stems from recommendations provided by an expert committee and the Drugs Technical Advisory Board. These bodies are responsible for evaluating the safety and efficacy of pharmaceutical products in India and advising the government on necessary policy changes. The move underscores a proactive approach to child safety in medication.
Impact on Consumers and Manufacturers
- For Parents: Parents and guardians should be aware of this new regulation and carefully check the labels of cough and cold medicines before administering them to children, especially those under four years old. It is crucial to consult a pediatrician for appropriate treatment options for young children.
- For Manufacturers: Pharmaceutical companies producing these FDCs must swiftly update their packaging and labeling to comply with the new government directive. Failure to do so could lead to regulatory penalties.
This restriction is part of ongoing efforts by the government to ensure the safety and appropriate use of medicines, particularly for vulnerable populations like young children. It highlights the importance of evidence-based recommendations from expert bodies in shaping public health policy.
This report is for informational purposes only and does not constitute medical advice. Always consult a healthcare professional.
Community Pulse · This story
How readers rate the outlook after reading this article. Anonymous · one vote per reader · updates live.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
Which specific medicines are affected by this new government rule?
The new rule affects fixed-dose combination medicines that contain both Chlorpheniramine Maleate and Phenylephrine Hydrochloride.
For what age group is the use of these medicines now prohibited?
These specific fixed-dose combination medicines are now prohibited for use in children below four years of age.
What action must manufacturers take regarding these medicines?
Manufacturers are now required to clearly display a warning on all associated product packaging stating that these medicines are not for use in children under four years.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
Apollo Hospitals Now Open 7 Days a Week for Routine Services
Apollo Hospitals has expanded its routine healthcare services to include Sundays, making outpatient consultations and diagnostic services available every day of the week. This move aims to improve access for busy individuals and families seeking timely medical care.
BreakingParliamentary Panel Proposes Cap on Private Hospital Room Charges at 3-Star Hotel Rates
A parliamentary committee has recommended capping private hospital room rents to match three-star hotel rates to improve healthcare affordability. The proposal comes amid rising private equity investments in the healthcare sector that have driven up valuations and treatment costs.
BreakingMaharashtra FDA Cancels 10 Ayurvedic Drug Licences Over Quality Violations
The Maharashtra Food and Drug Administration (FDA) has cancelled the manufacturing licenses of ten Ayurvedic drug makers following a statewide crackdown. Inspections revealed serious violations of quality control and manufacturing standards, with 135 other manufacturers receiving show-cause notices for non-compliance.
Related Stories
Apollo Hospitals Now Open 7 Days a Week for Routine Services
Apollo Hospitals has expanded its routine healthcare services to include Sundays, making outpatient consultations and diagnostic services available every day of the week. This move aims to improve access for busy individuals and families seeking timely medical care.
BreakingParliamentary Panel Proposes Cap on Private Hospital Room Charges at 3-Star Hotel Rates
A parliamentary committee has recommended capping private hospital room rents to match three-star hotel rates to improve healthcare affordability. The proposal comes amid rising private equity investments in the healthcare sector that have driven up valuations and treatment costs.
BreakingMaharashtra FDA Cancels 10 Ayurvedic Drug Licences Over Quality Violations
The Maharashtra Food and Drug Administration (FDA) has cancelled the manufacturing licenses of ten Ayurvedic drug makers following a statewide crackdown. Inspections revealed serious violations of quality control and manufacturing standards, with 135 other manufacturers receiving show-cause notices for non-compliance.
Alta Capital-Backed Logicap Acquires Xander's Warehousing Assets for ₹1500 Crore
Logicap, a four-year-old warehousing and logistics firm backed by Alta Capital, has acquired warehousing assets from Xander for a significant sum of ₹1500 crore. This strategic purchase expands Logicap's total portfolio to approximately 25 million square feet, marking its rapid growth in India's logistics infrastructure sector.